You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

8 Results
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    erlotinib - Incurable progressive NSCLC, with specific criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
erlotinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Oct 2022
Regimen
Cancer Type:
Gastrointestinal, 
Gastric / Stomach
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    For the treatment of metastatic gastric cancer (mGC) or adenocarcinoma of the gastroesophageal junction (GEJ) in adult patients, according to clinical criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
trifluridine / tipiracil
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Nov 2022
Drug
Other Name(s): Tarceva®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Oct 2022
Drug
Other Name(s): Zydelig™
Quick Link(s):
Drug Monograph, Patient Info Sheet
Feb 2022
Drug
Other Name(s): Kisqali™
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jan 2022
Drug
Other Name(s): Tykerb®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Dec 2022
Drug
Other Name(s): Xalkori®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jan 2022
Drug
Other Name(s): Rydapt®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jun 2022